Arcellx Inc. was acquired by Gilead Sciences in April 2026. ACLX no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Gilead Sciences, and their dates may not have been updated since.
Clinical trial readout dates for Arcellx Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.